Structural Insight into the Mode of Action of a Direct Inhibitor of Coregulator Binding to the Thyroid Hormone Receptor.

The development of nuclear hormone receptor antagonists that directly inhibit the association of the receptor with its essential coactivators would allow useful manipulation of nuclear hormone receptor signaling. We previously identified 3-(dibutylamino)-1-(4-hexylphenyl)-propan-1-one (DHPPA), an aromatic β-amino ketone that inhibits coactivator recruitment to thyroid hormone receptor β (TRβ), in a high-throughput screen. Initial evidence suggested that the aromatic β-enone 1-(4-hexylphenyl)-prop-2-en-1-one (HPPE), which alkylates a specific cysteine residue on the TRβ surface, is liberated from DHPPA. Nevertheless, aspects of the mechanism and specificity of action of DHPPA remained unclear. Here, we report an x-ray structure of TRβ with the inhibitor HPPE at 2.3-Å resolution. Unreacted HPPE is located at the interface that normally mediates binding between TRβ and its coactivator. Several lines of evidence, including experiments with TRβ mutants and mass spectroscopic analysis, showed that HPPE specifically alkylates cysteine residue 298 of TRβ, which is located near the activation function-2 pocket. We propose that this covalent adduct formation proceeds through a two-step mechanism: 1) β-elimination to form HPPE; and 2) a covalent bond slowly forms between HPPE and TRβ. DHPPA represents a novel class of potent TRβ antagonist, and its crystal structure suggests new ways to design antagonists that target the assembly of nuclear hormone receptor gene-regulatory complexes and block transcription

Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators

Thyroid hormone (3,5,3′-triiodo-l-thyronine, T3) is an endocrine hormone that exerts homeostatic regulation of basal metabolic rate, heart rate and contractility, fat deposition, and other phenomena (1, 2). T3 binds to the thyroid hormone receptors (TRs) and controls their regulation of transcription of target genes. The binding of TRs to thyroid hormone induces a conformational change in TRs that regulates the composition of the transcriptional regulatory complex. Recruitment of the correct coregulators (CoR) is important for successful gene regulation. In principle, inhibition of the TR-CoR interaction can have a direct influence on gene transcription in the presence of thyroid hormones. Herein we report a high throughput screen for small molecules capable of inhibiting TR coactivator interactions. One class of inhibitors identified in this screen was aromatic β-aminoketones, which exhibited IC50 values of ∼2 μm. These compounds can undergo a deamination, generating unsaturated ketones capable of reacting with nucleophilic amino acids. Several experiments confirm the hypothesis that these inhibitors are covalently bound to TR. Optimization of these compounds produced leads that inhibited the TR-CoR interaction in vitro with potency of ∼0.6 μm and thyroid signaling in cellular systems. These are the first small molecules irreversibly inhibiting the coactivator binding of a nuclear receptor and suppressing its transcriptional activity

Reactive nitrogen/oxygen species production by nitro/nitrosyl supramolecular ruthenium porphyrin complexes.

This manuscript reports on new nitro/nitrosyl Ru-based complexes, which were synthesized with the purpose of using them as precursors to obtain supramolecular ruthenium porphyrin species ({TPyP[Ru (NO2)(5,50-Mebipy)2]4}(PF6)4) and ({TPyP[Ru(NO)(5,50-Mebipy)2]4}(PF6)12). The photochemical and photophysical properties of these porphyrin species were investigated. Results show that the complex containing nitrite is able to produce NO by homolytic O?NO cleavage (FPPh NO = 0.05) while the {TPyP[Ru (NO)(5,50-Mebipy)2]4}(PF6)12 does it by direct labilization (FPPh NO = 0.53) of the Ru NO bond. Furthermore, a triplet quantum yield of 0.09 and 0.27 was observed for complexes containing nitrite and nitric oxide, respectively. The reactive oxygen species quantum yield for the complex {TPyP[Ru(NO) (5,50-Mebipy)2]4}(PF6)12 (0.78) is consistent with the sum of quantum yields NO release (0.53) and triplet state (0.27), which suggests that both processes participate in the formation of the reactive species. Our results show that combining these characteristics, NO production and triplet states, on the same platform could induce a synergic effect, leading to a considerable improvement in the photodynamic action of these complexes

Ruthenium(II)/triphenylphosphine complexes : an effective way to improve the cytotoxicity of lapachol.

This study reports on the synthesis of a new ruthenium(II) complex, cis-[Ru(PPh3)2(lap)2] (1) with two molecules of the natural product known as lapachol [lap = (2-hydroxy-3-(3-methyl-2-buthenyl)-1,4- naphthoquinone)] coordinated as bidentated by oxygen atoms and two monodentate PPh3 (triphenylphosphine) in a cis configuration. This neutral complex was characterized by spectroscopic analysis, single-crystal X-ray diffraction, elemental analysis, molar conductivity and cyclic voltammetry. In this study, ruthenium complex trans-[Ru(lap)(PPh3)2(phen)]PF6 (2) was used for comparison purposes. The interaction of ruthenium complexes (1) and (2) with CT-DNA was evaluated by UV?Vis and circular dichroism and it was observed that the complexes interact weakly with the CT-DNA. The fluorescence measurements suggest that complex (1) shows stronger interaction with HSA and BSA proteins compared to complex (2). Cytotoxicity assays against A549 (lung cancer), MDA-MB-231 (breast cancer) and V79 (non-tumoral lung) revealed that complex (2) is more active (lower IC50 values) than complex (1) and the cisplatin, used as a reference

Structural Insight into the Mode of Action of a Direct Inhibitor of Coregulator Binding to the Thyroid Hormone Receptor.

The development of nuclear hormone receptor antagonists that directly inhibit the association of the receptor with its essential coactivators would allow useful manipulation of nuclear hormone receptor signaling. We previously identified 3-(dibutylamino)-1-(4-hexylphenyl)-propan-1-one (DHPPA), an aromatic β-amino ketone that inhibits coactivator recruitment to thyroid hormone receptor β (TRβ), in a high-throughput screen. Initial evidence suggested that the aromatic β-enone 1-(4-hexylphenyl)-prop-2-en-1-one (HPPE), which alkylates a specific cysteine residue on the TRβ surface, is liberated from DHPPA. Nevertheless, aspects of the mechanism and specificity of action of DHPPA remained unclear. Here, we report an x-ray structure of TRβ with the inhibitor HPPE at 2.3-Å resolution. Unreacted HPPE is located at the interface that normally mediates binding between TRβ and its coactivator. Several lines of evidence, including experiments with TRβ mutants and mass spectroscopic analysis, showed that HPPE specifically alkylates cysteine residue 298 of TRβ, which is located near the activation function-2 pocket. We propose that this covalent adduct formation proceeds through a two-step mechanism: 1) β-elimination to form HPPE; and 2) a covalent bond slowly forms between HPPE and TRβ. DHPPA represents a novel class of potent TRβ antagonist, and its crystal structure suggests new ways to design antagonists that target the assembly of nuclear hormone receptor gene-regulatory complexes and block transcription

Ru(II)?thyminate complexes : new metallodrug candidates against tumor cells.

Herein, we used thymine (HThy) as a ligand to form two new ruthenium(II) complexes with formula [Ru(PPh3)2(Thy)(bipy)]PF6 (1) and [Ru(Thy)(bipy)(dppb)]PF6 (2). The complexes were characterized by spectroscopic, spectrometric and X-ray crystallography analyses. Complexes 1 and 2 can interact with ctDNA presenting binding constants, Kb, of 0.4 and 1.2 ? 103 M?1, respectively. Their cytotoxic activities towards tumor cell lines (B16-F10, HepG2, K562 and HL-60) and non-tumor cells (PBMCs) were evaluated using the Alamar blue assay. Complex 1 exhibits high cytotoxicity against tumor cells, showing IC50 values of 0.01 and 1.81 ?M against the HL-60 and HepG2 cell lines, respectively. Therefore, compound 1 can be considered as a promising antitumor metallodrug

Structural isomerism of Ru(II)-carbonyl complexes : synthesis, characterization and their antitrypanosomal activities.

New complexes with the general formula [RuCl(CO)(dppb)(diimine)]PF6, [dppb = 1,4-bis(diphenylphosphino) butane; diimine = 2,20-bipyridine (bipy) or 1,10-phenanthroline (phen)], were prepared. Thus, the complexes ct-[RuCl(CO)(dppb)(bipy)]PF6 (1), ct-[RuCl(CO)(dppb)(phen)]PF6 (2), tc-[RuCl(CO)(dppb)(bipy)]PF6 (3), tc-[RuCl(CO)(dppb)(phen)]PF6 (4), cc-[RuCl(CO)(dppb)(bipy)]PF6 (5) and cc-[RuCl(CO)(dppb)(phen)]PF6 (6) were obtained and characterized. In this case, the first letter in the prefixes indicates the position of CO with respect to the chlorido ligand and the second one is related to the phosphorus atoms. The compositions of the complexes were confirmed by analytical techniques and an octahedral environment around the ruthenium was confirmed by single-crystal X-ray diffraction of the complexes ct-[RuCl(CO)(dppb)(bipy)]PF6 and cc-[RuCl(CO)(dppb)(phen)]PF6. The oxidation potentials of the complexes were determined by cyclic voltammetry and it was found that they vary according to the CO position in the complexes. In order to obtain information on the stability of the ct, tc and cc-[RuCl(CO)(dppb)(bipy)]PF6 (1), (3) and (5) isomers, computational studies were carried out, and they showed large differences between the HOMO/LUMO energies. As monitored by 13C NMR, the stability of the complexes with respect to CO displacement, for at least 72 h, in DMSO-d6 solution, is independent of the CO position in the complexes. Pharmacological evaluation of the complexes against the Trypanosoma cruzi parasite revealed the structure?activity relationships, showing that the presence and position of the CO ligand in the complexes are relevant for the antiparasitic activity of the compounds. The most active compound, the tc-[RuCl(CO)(dppb)(bipy)]PF6 isomer, presented potent antiparasitic activity, which was achieved by causing oxidative stress followed by parasite cell death through necrosis. Thus, the findings presented here demonstrate that the use of a carbonyl ligand provides stability and pharmacological properties to ruthenium/diphosphine/diimine complexes